Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Belacabnagene Franleucel · NKX-019

Cell therapy (CAR-NK) · Kills target cells, directed at CD19 · developed by Nkarta

Phase 1/2 Most advanced trial
NKTX Developer
1 Registered trials

What is Belacabnagene Franleucel?

Belacabnagene franleucel is an allogeneic, off-the-shelf natural killer cell therapy engineered to express membrane-bound IL-15 and a CD19-directed chimeric antigen receptor with OX40 and CD3-zeta signaling domains. It targets CD19-expressing cells and is being studied in lupus nephritis and primary membranous nephropathy.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
NKX-019
Drug type
Cell therapy (CAR-NK)
Targets
CD19 (antigen)
Mechanism
Kills target cells, directed at CD19
Pathways
CD19-directed cytotoxicity, pro-inflammatory cytokine secretion
Therapy area
Immunology, Renal & urology
Developer
Nkarta, Inc. (NKTX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
JG828PW4NT

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06557265 Phase 1/2 Lupus Nephritis Recruiting NKTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Lupus NephritisPrimary Membranous Nephropathy

Other drugs acting on CD19

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the NKTX page.

Follow NKTX, the company behind Belacabnagene Franleucel

See NKTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NKTX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.